DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT

Company Announcement - Devonian Health Group Inc. has appointed Dennis Turpin as Chief Financial Officer, effective immediately, while he will continue to serve on the Board of Directors [1][3] - Turpin has over 25 years of experience in the biopharmaceutical industry, focusing on finance, capital markets, business development, and mergers and acquisitions [2] - He replaces Viktoria Krasteva, who will assist in the transition until February 27, 2026 [4] Stock Options - A total of 25,000 stock options were granted to Turpin, vesting immediately at an exercise price of $11.50 for a period of 10 years [4] - The company corrected a previous press release regarding the granting of stock options, adjusting the exercise price from $0.18 to $0.19, which is now $11.40 on a post-consolidation basis [5] Company Overview - Devonian Health Group Inc. is a clinical stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory diseases, including atopic dermatitis, radiodermatitis, and ulcerative colitis [6] - The company also develops high-value cosmeceutical products and operates a subsidiary, Altius Healthcare LP, for selling prescription pharmaceuticals in Canada [7] - Incorporated in 2015, Devonian is headquartered in Quebec, Canada, and is publicly traded on the TSX Venture Exchange and quoted on the OTCQB Venture Market [8]